Chile's National Advisory Committee on Immunization (CAVEI): Evidence-based recommendations for public policy decision-making on vaccines and immunization

Jeanette Dabanch a, Cecilia González b, Jaime Cerda c, Johanna Acevedo d, Mario Calvo e, Eduardo Díaz f, María Enideiza g, Jaime Inostroza h, Jaime Rodríguez i, Adiela Saldaña j, Solange Santillana k, Nathalie El Omeiri l, Magdalena Bastías m,*

a Hospital Clínico Universidad de Chile, Santos Dumont 999, Santiago, Chile
b Departamento de Deportes y Educación Física, Universidad de Chile, Santiago, Chile
c Departamento de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile
d Departamento de Epidemiología, Ministerio de Salud, Enrique Mac Iver 541, Santiago, Chile
e Instituto de Medicina, Facultad de Medicina, Universidad Austral de Chile, Coronel Santiago Bueras 1003, Valdivia, Chile
f Facultad de Medicina, Universidad de Chile, Av. Independencia 1027, Santiago, Chile
g Facultad de Medicina, Universidad de La Frontera, Avenida Francisco Salazar 01145, Temuco, Chile
h Unidad de Infectología Pedíatrica, Clínica Alemana, Av. Vitacura 5951, Santiago, Chile
i Farmacovigilancia de vacunas, Instituto de Salud Pública, Av. Marathon 1000, Santiago, Chile
j SEREMI de Salud Región de Valparaíso, Melgarejo 669, piso 6., Valparaíso, Chile
k Departamento de Family, Health Promotion and Life Course PAHO/WHO, 525 23rd St NW, Washington DC 20037, United States
l Departamento de Inmunizaciones, Ministerio de Salud, Monjitas 565, p7, Santiago, Chile
m* Corresponding author at: Departamento de Inmunizaciones Ministerio de Salud, Monjitas 565 piso 7, Santiago 8320070, Chile.
E-mail address: bastiasmalu@gmail.com (M. Bastías).

**Abbreviations:** NITAG, National Immunization Technical Advisory Group; CAVEI, Comité Asesor en Vacunas y Estrategias de Inmunización; PAHO, Pan American Health Organization; WHO, World Health Organization; CDC, United States Centers for Disease Control and Prevention; GVAP, Global Vaccine Action Plan; GNN, Global NITAG Network; MoH, Ministry of Health; BCG, Bacillus Calmette–Guérin vaccine; DTP3, Diphtheria-tetanus-pertussis vaccine third dose; MMR1, Measles–mumps–rubella vaccine first dose; ToR, Terms of reference; SOP, Standard operating procedures; NIPH, National Institute of Public Health; SAGE, Strategic Advisory Group of Experts on Immunization; FDA, United States Food and Drug Administration, EMA, European Medicines Agency; EVIPNET, Evidence informed policy networks.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

National Immunization Technical Advisory Groups (NITAGs) are multidisciplinary groups of national experts responsible for providing independent, evidence–based advice to policy makers and programme managers on policy issues related to immunization and vaccines. The Global Vaccine Action Plan (GVAP) calls for all Member States to establish or have access to such a NITAG by 2020 [1] In 2017, an increased number of NITAGs met GVAP functionality criteria with respect to 2016 (64% vs. 73%). These criteria consist of six process indicators: (i) legislative or administrative
basis for the advisory group; (ii) formal written terms of reference; (iii) at least five different areas of expertise represented among core members, (iv) at least one meeting per year; (v) circulation of the agenda and background documents at least one week prior to meetings; and (vi) mandatory disclosure of any conflict of interest [2].

The improvement in advisory groups capacity to meet the functionality criteria reflects the dynamic nature of the NITAG community and the support offered by the Global NITAG Network (GNN) and WHO Regional Offices to build national sustainable capacities through the provision of training material, training and evaluation sessions and the facilitation of peer-to-peer support meetings [2].

The Chilean NITAG, CAVEI, is mandated by decree to provide the Ministry of Health (MoH) with advice on immunization programmes, strategies and policy formulation. CAVEI can provide advice on the use of any vaccine across de life span for routine immunization or mass vaccination campaigns. Ultimate decisions made by the MoH may fully, partially, or not take CAVEI's recommendations into account.

CAVEI meets the GVAP functionality criteria and sets its own agenda taking into consideration MoH requests.

2. Description and background

Establishment of CAVEI was first promulgated in December 2009 by ministerial decree N° 2028 [3], however, advisory group on vaccines activity in Chile dates back to the 1990s. Currently, the committee operates under the mandate of the ministerial decree N° 16 promulgated in April 2013 [4].

As an advisory committee to the MoH, CAVEI came to join a solid and long tradition of public health administration, planning, and health service delivery both in general and regarding immunization policy in particular (Fig. 1).

The Chilean NITAG, CAVEI, is mandated by decree to provide the Ministry of Health (MoH) with advice on immunization programmes, strategies and policy formulation. CAVEI can provide advice on the use of any vaccine across de life span for routine immunization or mass vaccination campaigns. Ultimate decisions made by the MoH may fully, partially, or not take CAVEI's recommendations into account.

CAVEI meets the GVAP functionality criteria and sets its own agenda taking into consideration MoH requests.

Table 1. CAVEI composition by year

<table>
<thead>
<tr>
<th>Year</th>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>1765</td>
<td>Variolation</td>
</tr>
<tr>
<td>1805</td>
<td>Smallpox vaccine</td>
</tr>
<tr>
<td>1808</td>
<td>General board of vaccines</td>
</tr>
<tr>
<td>1887</td>
<td>Compulsory Vaccination Act</td>
</tr>
<tr>
<td>1896</td>
<td>Rabies vaccine</td>
</tr>
<tr>
<td>1918</td>
<td>Mass smallpox vaccination</td>
</tr>
<tr>
<td>1949</td>
<td>BCG vaccine</td>
</tr>
<tr>
<td>1950</td>
<td>Smallpox eradication</td>
</tr>
<tr>
<td>1954</td>
<td>Diphtheria Pertussis vaccine</td>
</tr>
<tr>
<td>1961</td>
<td>Polio vaccine</td>
</tr>
<tr>
<td>1964</td>
<td>Measles vaccine</td>
</tr>
<tr>
<td>1975</td>
<td>Diphtheria Tetanus Pertussis vaccine</td>
</tr>
<tr>
<td>1978</td>
<td>Cease of poliovirus circulation</td>
</tr>
<tr>
<td>1982</td>
<td>Influenza vaccine</td>
</tr>
<tr>
<td>1990</td>
<td>Measles Mumps Rubella vaccine</td>
</tr>
<tr>
<td>1992</td>
<td>Measles elimination</td>
</tr>
<tr>
<td>1997</td>
<td>Haemophilus influenzae type b vaccine</td>
</tr>
<tr>
<td>2005</td>
<td>Hepatitis B vaccine</td>
</tr>
<tr>
<td>2010</td>
<td>Pneumococcal polysaccharide vaccine</td>
</tr>
<tr>
<td>2015</td>
<td>Inactivated poliovirus vaccine</td>
</tr>
<tr>
<td>2018</td>
<td>Pertussis vaccination in pregnancy</td>
</tr>
<tr>
<td>2019</td>
<td>Hepatitis B vaccine newborns</td>
</tr>
</tbody>
</table>

Fig. 1. Chile's vaccination history timeline. *Regions of Arica y Parinacota and Biobío. Extended to the whole country in 2018. Source: Immunization Department, Ministry of Health [6].
departments and a representative of the National Regulatory Authority, Institute of Public Health (IPH). To date, ex-officio members have contributed to the committee with their expertise in public policy, public administration, immunizations, paediatric infectious diseases, epidemiology, pharmacy, and vaccine pharmacovigilance. Liaison membership has recently been adopted by CAVEI and a representative of the Chilean Society of Infectious Diseases was appointed as a member of the committee in 2017.

3. Functioning and working dynamics

The Terms of reference (ToR) of CAVEI were first stated in 2009, shortly followed by the first version of the SOP. As complementary guidance documents, ToR and SOP have defined the committee operation mode, regulating its composition, members' nomination process, core member's rotation, code of conduct, declaration of conflict of interest, plenary meetings frequency, composition of working groups or subcommittees, evidence-based recommendation process, basis for decision making, financial support from the MoH for elementary functioning, communication with authorities, report of activities (meeting minutes) and work dissemination.

CAVEI's plenary meetings are held monthly and supplementary meetings are scheduled as needed. A quorum of two thirds of core members and two ex-officio members are required to start a plenary session. Declaration of interest must precede the start of each session. Recommendations are voted by core members only. Core members with declared interests are asked to recuse themselves from participating in the discussion and decision making of the issues relating to that interest.

Expenses associated with CAVEI meetings (location, food and travel) and one salary for the executive secretary position are funded by the MoH. The executive secretary's duties entail administration, management, evidence search, and manuscript drafting. Communication flow within CAVEI and with other parties centralizes in the Executive Secretariat.

The current panel of experts has established a petit comité for early processing of MoH inputs requests, prompt coordination before emergency consultations (e.g. immunization strategies in natural disasters and disease outbreaks), and quick response to minor to moderate tasks including last-minute calls for meetings with health authorities, and drafts approval for circulation within the MoH for elementary functioning, communication with authorities, report of activities (meeting minutes) and work dissemination.

Evidence search and early analysis leads to the generation of a comprehensive body of evidence that helps working groups in addressing questions raised and also in identifying the weight of information gaps relative to the topic under study. CAVEI completes a ten–step process for recommendation development, as follows:

1. Understanding the context of the question raised.
2. Study of the epidemiological situation.
3. Identification of target population or risk groups.
5. Evidence search and critical assessment.
7. Recommendation drafting and first circulation for members review.
8. Discussion, consensus and closure of the recommendation in plenary session, extraordinary session or by electronic mail if under time constraints.
9. Communication of the recommendation to the Immunization Department and public dissemination.
10. Feedback from the Immunization Department stating acceptance or decline of the recommendation.

The MoH makes ultimate decisions based on the recommendations submitted by CAVEI, along with other information such as manufacturing of vaccines, product registration and required legislative changes. The Immunization Department is in charge of publishing CAVEI's work on its website [https://vacunas.minsal.cl/cavei/recomendaciones-cavei], including accepted and declined recommendations, minutes, and position papers. To date, there is 88% acceptance of CAVEI's recommendations.

5. CAVEI’s evaluation

Stemming from WHO and GNN recommendations, the evaluation of a NITAG's performance helps advisory groups assess how their intended purpose is being met and identify strengths and opportunities for growth. From a networks perspective, the assessment of NITAGs helps countries know where they stand and allows for monitoring of progress at the regional or global levels [7,9].

Once the six NITAG criteria are satisfied, the opportunity for NITAGs to assess their performance by incorporating various perspectives and interests is at hand. Tools for a more complete eval-
ution are the Indicators to assess National Immunization Technical Advisory Groups (NITAGs) by Blau et al. [9] and the SIVAC Evaluation Tool for National Immunization Technical Advisory Groups (NITAGs) [10], both available for download at the NITAG Resource Centre website (http://www.nitag-resource.org). Countries may review the indicators annually to evaluate their progress toward achieving and institutionalizing more standardized and evidence-based processes for immunization policymaking.

Recently, the US-CDC, in collaboration with WHO and other Global NITAG partners, and upon request from the Global NITAGs Network, developed a simplified Assessment tool for National Immunization Technical Advisory Groups [11] that considered three areas of performance: functionality, quality of work processes and outputs, and integration of the committee into the MoH policy process. The tool was adapted from SIVAC material and incorporated information from NITAG-related publications and field experience of partners.

Previous to the application of evaluation tools, CAVEI assessed its structure and functioning using National Immunization Technical Advisory Groups (NITAGs): Guidance for their establishment and strengthening by Philippe Duclos [7]. This pre-evaluation analysis shed light on CAVEI's growth in the past years and, consequently, on the need to update the committee's SOP. The new version of the standard operating procedures provides more detail on core-members’ rotation, development of recommendations, working groups’ formation, and communications with authorities.

In 2018, CAVEI underwent two evaluations. The first was a self-assessment using the Indicators to assess National Immunization Technical Advisory Groups (NITAGs) [9], which consists of 17 processes, output, and outcome indicators. The application of this tool provided CAVEI with a broad picture of satisfactory performance.

The second evaluation was the pilot test of the Assessment tool for National Immunization Technical Advisory Groups. It evaluates functionality, quality of work processes and outputs, and integration of a NITAG into the MoH policy process. It was conducted over three days. An external consultant coordinated the assessment, which involved individual interviews with all NITAG members/secretariat followed by a group discussion on the last day. An expert in qualitative studies conducted the interviews using an open-ended questionnaire that was adapted to the profile and role of each interviewee. During the group session that lasted two hours, NITAG members and the secretariat jointly filled the NITAG assessment tool. The individual interviews were crucial to prompt the discussions and facilitate the application of the tool. For the purpose of piloting the NITAG assessment tool, interviews were limited to CAVEI members only. However, future applications of this tool may consider including immunization stakeholders, scientific and professional organizations.

Results show that CAVEI is an independent and credible advisory group with a solid administrative basis, clear conflict of interest management policy, and practices that serve transparency purposes. These qualities allow CAVEI to publicly support authorities in times of crisis or questioning of immunization policies, and position papers of the committee are examples of this.

As an advisory body to the Ministry of Health, it is essential for CAVEI to maintain its independence and credibility, as well as the quality of its work processes and the soundness of its recommendations. The continuity of CAVEI’s intended purpose lies in the permanent alignment with the needs and priorities of health authorities.

CAVEI’s organizational flexibility in addressing inputs requests from the health authorities is a remarkable strength. In addition to the monthly frequency of meetings, supplementary meetings and the formation of a subcommittee comprised of a few members to respond to emergency consultations illustrates CAVEI members’ commitment to respond to the needs of the MoH in particular and to the population’s health needs, overall. Also, CAVEI’s working dynamics has allowed the committee to increase productivity in terms of number of recommendations issued per year.

The composition of CAVEI provides the committee with outstanding technical quality, both on the panel of experts and on the Secretariat. The expansion of profiles within the committee could be implemented incorporating new core, liaison or ex-officio members.

CAVEI seems to find itself in an advanced stage of NITAG development, possibly one near consolidation. However, functionality challenges are always to be foreseen and proactive planning and action shall never cease. The health authorities must continue funding CAVEI’s essential functioning and encourage its engagement in technical exchanges with other NITAGs and immunization networks.

Acknowledgements

We thank PAHO’s Department of Family, Health Promotion and Life Course for facilitating this evaluation, the United States Centers for Disease Control and Prevention (CDC), Global Immunization Division, especially Abigail Sheffer and Kathy Cavallaro for their technical and financial support, the Argentinian Institute of Clinical and Effectiveness Health Policy, for their support during the evaluation (Juan Alonso, Maria Belizan and Daniel Jones), and the Global NITAGs Network, and its secretariat at the World Health Organization for their inputs and collaboration.
Declaration of Competing Interest

JD has no conflicts of interests. CG has no conflicts of interests. JC has no conflicts of interests. JA has no conflicts of interests. MC has no conflicts of interests. ED has no conflicts of interests. ME works as immunization coordinator for a private hospital that purchases vaccines from different manufacturers and declares to have no conflicts of interests relevant to this paper. JI has no conflicts of interests. JR has no conflicts of interests. AS has no conflicts of interests. SS has no conflicts of interests. NE has no conflicts of interests. MB has no conflicts of interests.

References


